Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

10.95USD
19 Jul 2019
Change (% chg)

$-0.62 (-5.36%)
Prev Close
$11.57
Open
$11.66
Day's High
$11.70
Day's Low
$10.70
Volume
975,633
Avg. Vol
515,308
52-wk High
$48.25
52-wk Low
$10.70

Ivers-Read, Gillian 

Ms. Gillian C. Ivers-Read is Co-Founder, Executive Vice President, Chief Regulatory Officer of the Company. Ms. Ivers-Read is one of our co-founders and has served as our Executive Vice President and Chief Regulatory Officer since our inception. Previously, Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation (acquired in 2008), beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read received a B.Sc. in pharmacology from University College London.

Basic Compensation

Total Annual Compensation, USD 628,158
Restricted Stock Award, USD 642,730
Long-Term Incentive Plans, USD --
All Other, USD 493,132
Fiscal Year Total, USD 1,764,020

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018